Newsletter Tool

Today’s Big News

Sep 5, 2024

Eli Lilly jumps deeper into AI with $409M Genetic Leap deal

IN8bio halts phase 2 glioblastoma trial, lays off half of workforce to focus on leukemia cell therapy

Eli Lilly closes distance on Novo with another clutch of positive data on once-weekly insulin prospect

Gene therapy biotech Medera looks back to SPAC as way to go public

BioMarin outlines road map to $4B in sales by 2027 amid portfolio, organizational shake-ups

Novartis ignites new stage of Voyager pact with $15M capsid deal

Chlamydia may lurk unseen in intestines, requiring a new antibiotic approach

Astellas Gene Therapies to turn out the lights at South San Francisco production plant

Featured

Eli Lilly jumps deeper into AI with $409M Genetic Leap deal

By Nick Paul Taylor

Eli Lilly has vaulted into an AI-enabled drug discovery deal, partnering with RNA specialist Genetic Leap in a pact worth up to $409 million in upfront and milestone payments.

Lilly closes distance on Novo with another clutch of positive data on once-weekly insulin prospect

By Fraiser Kansteiner

Early Thursday, Lilly unveiled positive topline results from a pair of phase 3 trials—QWINT-1 and QWINT-3—assessing its once-a-week basal insulin candidate called efsitora alfa. Both studies met their primary endpoints, with efsitora achieving non-inferior A1C reductions when pitted against two common daily insulins.

IN8bio halts phase 2 glioblastoma trial, lays off half of workforce to focus on leukemia cell therapy

By Darren Incorvaia

Just a few months after dosing the first patient in a phase 2 trial for newly diagnosed glioblastoma, IN8bio is hitting the brakes—and laying off half of its workforce.

Fierce Biotech Editor-in-Chief Ayla Ellison Talks Shop with Michelle Benz on the Future of Biotech.

Gene therapy biotech Medera looks back to SPAC as way to go public

By James Waldron

You don’t hear about SPAC mergers too much these days, but Medera is set to change that as the cardiovascular-disease-focused biotech dusts off this lesser-used pathway to the public markets.

BioMarin outlines road map to $4B in sales by 2027 amid portfolio, organizational shake-ups

By Zoey Becker

The company's game plan includes five new indications for dwarfism drug Voxzogo through 2031, which could represent a $5 billion opportunity covering a patient population of 420,000.

Novartis ignites new stage of Voyager pact with $15M capsid deal

By Nick Paul Taylor

Novartis is opening a new frontier in its collaboration with Voyager Therapeutics, paying $15 million to take up its option on a novel capsid for use in a rare neurological disease gene therapy program.

Chlamydia may lurk unseen in intestines, requiring a new antibiotic approach

By Darren Incorvaia

The bacterium Chlamydia trachomatis is best known for infecting genitals, causing the sexually transmitted infection known as chlamydia. But a new study has found that these sneaky cells can also infiltrate our guts, building a hidden supply of bacteria that could then leak to the genitals and cause reoccurring infections.

Astellas Gene Therapies to turn out the lights at South San Francisco production plant

By Fraiser Kansteiner

Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a California production plant.

Humana exiting Medicare Advantage in 13 markets

By Noah Tong

Humana is pulling back from Medicare Advantage markets and cutting benefits next year. The insurer expects it will lose thousands of members and supplemental benefit utilization will be high toward the end of this year.

Fierce podcasts

Don’t miss an episode

Driving flu vaccine uptake in the post pandemic era

In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond.

Minimizing plastics use and risk in healthcare

The TROP2 race for supremacy

Resources

Whitepaper

Building a “Best Practice” Commercial Organization in Biopharma

We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned.

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.